Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131167 · ClinicalTrials.gov registry record · Phase 1
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
A Phase 1 study of Ocular Hypertension and Primary Open Angle Glaucoma (POAG), sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT03131167 is a Phase 1 study of Ocular Hypertension and Primary Open Angle Glaucoma (POAG) that has completed, run by Shire. The registered enrollment target is 63 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03131167, a Phase 1 study of Ocular Hypertension and Primary Open Angle Glaucoma (POAG), has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
Conditions Studied
Interventions
- DRUG SHP639 (n=60)
- DRUG Placebo Comparator (n=24)
Study Locations (1)
Massachusetts
- Central Contact - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-05-10 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03131167
The ClinicalTrials.gov registry entry for NCT03131167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (77% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which SHP639 (n=60) is the first listed.
NCT03131167 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03131167 about?
NCT03131167 is a clinical study titled "Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma". Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
What is the current status of trial NCT03131167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2017-05-10. Estimated completion is 2018-05-30.
What conditions does trial NCT03131167 study?
This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma (POAG).
What interventions are being tested in trial NCT03131167?
The interventions under investigation include: SHP639 (n=60) (DRUG), Placebo Comparator (n=24) (DRUG).
Who is sponsoring clinical trial NCT03131167?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03131167 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
Explore more on PlainTrial
Ocular Hypertension
All registered trials for this condition
Primary Open Angle Glaucoma (POAG)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.